-
Prague’s Concert for the Future Kicks Off on Wenceslas Square
-
Apple Watch Live Rewind and Siri Recap: Privacy Concerns and Social Awkwardness
-
Prince William and Princess of Wales to Announce Earthshot Prize Winners in Mumbai
-
Rob Green Transforms Nottingham Central Library into Intimate Stage for Undercover Tour Finale
-
Indonesia Forest Fires: Health Crisis, Diplomatic Strains and the Search for Solutions
-
Proposed Fiscal Anchor Threatens South Africa’s Constitutional Rights Amid Health Crisis
-
BYD Dolphin G Leasing Deal: Plug-in Hybrid Supermini Available from £174 a Month
-
Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities
-
JUEL Group Expands from Real Estate to Hospitality with Hyatt Centric Malta Opening
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
Mixed results for Lyme disease vaccine hit Valneva shares
An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday, however the latter firm's shares fell because the clinical trial did not reach its main goal.
There are currently no approved vaccines to treat Lyme disease -- the world's most common illness spread to infected ticks -- in humans.
The new vaccine candidate "demonstrated more than 70 percent efficacy in preventing Lyme disease in individuals aged five years and above" during a phase 3 clinical trial, the US and French-Austrian companies said in a joint statement.
However, because there were fewer cases of Lyme disease than expected during the study period, the trial did not meet its primary endpoint, they added.
Following the announcement, Valneva's share price plunged more than 38 percent at around noon GMT on the Paris stock exchange, which was otherwise up 0.7 percent.
Prizer said in the statement it remains "confident in the vaccine's potential and is planning submissions to regulatory authorities" in the United States and European Union.
"These results bring us a step closer to our goal of delivering a much-needed vaccine to help protect against Lyme disease," Valneva CEO Thomas Lingelbach added.
The vaccine LB6V, formerly called VLA15, creates antibodies in humans that fight off the bacteria Borrelia burgdorferi, which causes Lyme disease.
The condition is rarely fatal, but people bitten by an infected tick often get a rash and suffer flu-like symptoms including muscle and joint ache, headache, nausea and vomiting.
In some cases, it can also cause neurological problems.
Research in 2022 estimated that more than 14 percent of the global population has had the disease, warning that transmission rates could increase as climate change brings longer, drier summers.
C.Meier--BTB